Medicare Spending on Drugs and Biologics Not Recommended for Coverage by International Health Technology Assessment Agencies

J Gen Intern Med. 2019 Nov;34(11):2319-2321. doi: 10.1007/s11606-019-05149-6.

Alexander C Egilman^{1

2}, Joshua D Wallach^{1

2

3}, Sanket S Dhruva⁴, Gregg S Gonsalves^{1

5}, Joseph S Ross^{6

7

8

9

10}

¹ Collaboration for Research Integrity and Transparency, Yale Law School, New Haven, CT, 06510, USA.
² Center for Outcomes Research and Evaluation (CORE), Yale New Haven Hospital, New Haven, CT, 06510, USA.
³ Department of Environmental Health Sciences, Yale School of Public Health, New Haven, CT, 06510, USA.
⁴ Department of Medicine, University of California, San Francisco School of Medicine, San Francisco, CA, 94115, USA.
⁵ Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, 06510, USA.
⁶ Collaboration for Research Integrity and Transparency, Yale Law School, New Haven, CT, 06510, USA. joseph.ross@yale.edu.
⁷ Center for Outcomes Research and Evaluation (CORE), Yale New Haven Hospital, New Haven, CT, 06510, USA. joseph.ross@yale.edu.
⁸ Section of General Medicine, Department of Internal Medicine, Yale School of Medicine, P.O. Box 208093, New Haven, CT, 06520, USA. joseph.ross@yale.edu.
⁹ Department of Health Policy and Management, Yale School of Public Health, New Haven, CT, 06510, USA. joseph.ross@yale.edu.
¹⁰ National Clinician Scholars Program, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, 06510, USA. joseph.ross@yale.edu.

No abstract available

Publication types